SynthesisEuropean journal of clinical pharmacology2026
Effect of glucocorticoids on smell sensation in patients with non-traumatic olfactory disorders: a systematic review and meta-analysis.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of glucocorticoids (GCs) for treating non-traumatic olfactory disorders (ODs) remains controversial, with existing meta-analyses showing inconsistent results, largely due to variations in included studies and a lack of etiology-specific analysis.
methodsThis systematic review and meta-analysis followed a pre-registered protocol (PROSPERO: CRD42022319449). We searched four databases up to December 2025 for studies assessing GCs therapy in adults with non-traumatic ODs. Efficacy was analyzed by etiology, with the primary outcome being the standardized mean difference (SMD) in objective or subjective olfactory score change.
resultsThirty-four studies were included. GCs therapy significantly improved olfactory function in patients with COVID-19-related ODs (13 studies, 1538 patients, SMD = 0.53, 95% CI: 0.27-0.79), nasal polyposis (9 studies, 2022 patients, SMD = 0.56, 95% CI: 0.39-0.72), and chronic rhinosinusitis with nasal polyps (5 studies, 318 patients, SMD = 0.89, 95% CI: 0.18-1.59). No significant benefit was found for chronic rhinosinusitis without polyps (4 studies, 464 patients, SMD = 0.25, 95% CI: -0.03-0.53) or allergic rhinitis (3 studies, 240 patients, SMD = 0.50, 95% CI: -0.02-1.01). Significant heterogeneity was observed for the positive outcomes. Given the significant heterogeneity (I² > 50%), subgroup analyses were performed based on the method of olfactory assessment, treatment duration, formulation, and control group type.
conclusionThe efficacy of GCs in olfactory dysfunction is probably etiology-dependent. They are most beneficial for ODs related to nasal polyps. For COVID-19-related ODs, short-term intranasal GCs may be effective, while evidence for allergic rhinitis remains inconclusive.
Indexed as
Identifiers
42507165What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.